AbbVie Inc (N:ABBV)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1 N Waukegan Rd NORTH CHICAGO IL 60064 |
| Tel: | 1-847-9352211 |
| Website: | https://www.abbvie.com |
| IR: | See website |
| Key People | ||
| Richard A. Gonzalez Chairman of the Board, Chief Executive Officer | Kevin K. Buckbee Senior Vice President, Controller | Robert A. Michael President, Chief Operating Officer |
| Scott T. Reents Chief Financial Officer, Executive Vice President | Timothy J. Richmond Chief Human Resource Officer, Executive Vice President | Perry C. Siatis Executive Vice President, General Counsel, Company Secretary |
| Nicholas J. Donoghoe Executive Vice President, Chief Business and Strategy Officer | Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer | Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer | Thomas J. Hudson Senior Vice President, Chief Scientific Officer - Global Research |
| Business Overview |
| AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, AbbVie Inc revenues decreased 6% to $54.32B. Net income applicable to common stockholders decreased 59% to $4.82B. Revenues reflect United States segment decrease of 7% to $39.81B, Europe segment decrease of 27% to $3.04B. Net income also reflects Research and development increase of 8% to $6.76B (expense), Advertising Expense increase of 10% to $2.2B (expense). |
| Employees: | 50,000 as of Jan 31, 2024 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $346,765M as of Dec 31, 2023 |
| Annual revenue (TTM): | $54,318M as of Dec 31, 2023 |
| EBITDA (TTM): | $25,413M as of Dec 31, 2023 |
| Net annual income (TTM): | $4,819M as of Dec 31, 2023 |
| Free cash flow (TTM): | $11,523M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $46,569M as of Dec 31, 2023 |
| Shares outstanding: | 1,770,646,983 as of Mar 4, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.